
Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12439/2823
Title: | Impact of a Virtual Heart Failure Unit on Mortality Rates. |
Northern Health Authors: | Ahthavan Narendren;V Hannah;R Clayton;S Noori;N Sharma;C Wong;Francis Ponnuthurai;William van Gaal;Donald Campbell;Bill Shearer;Rabin Sinnappu;Gautam Vaddadi;Prasanna Venkataraman |
Northern Health first author: | Ahthavan Narendren |
Northern Health last author: | Prasanna Venkataraman |
Northern Health affiliation: | (Narendren, Hannah, Clayton, Noori, Sharma, Wong, Ponnuthurai, van Gaal, Campbell, Shearer, Sinnappu, Vaddadi, Venkataraman) Northern Health, Epping, VIC, Australia |
Authors: | Narendren A.;Hannah V.;Clayton R.;Noori S.;Sharma N.;Wong C.;Ponnuthurai F.;van Gaal W.;Campbell D.;Shearer B.;Sinnappu R.;Vaddadi G.;Venkataraman P. |
Citation: | Heart Lung and Circulation. Conference: 72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. Perth Convention and Exhibition Centre, Perth Australia. 33(Supplement 4) (pp S269-S270), 2024. Date of Publication: August 2024. |
Issue Date: | 1-Aug-2024 |
Abstract: | Background: Heart failure is a major cause of mortality in in Australia. In November 2021, a dedicated virtual heart failure unit (VHFU) was created at Northern Health to reduce inpatient length of stay and up-titrate guideline-directed medical therapy. We sought to assess change in HF over time and impact of VHFU on mortality. Method(s): A retrospective audit of unplanned admissions to the cardiology department with acute decompensated HF across two time periods (TP1: July 2018-December 2019 and TP2 November 2021-January 2024) excluding COVID period. Mortality data was collected until February 2024. Result(s): A total of 641 patients were admitted across both time periods. 143 patients were admitted to VHFU (63% male vs 37% female) and 498 patients were not admitted to the VHFU (59% male vs 41% female). There was no significant difference in the age (72 vs 72, p=0.27) or gender (63% vs 59%, p=0.43) in patients admitted to VHFU and those discharged home. At 30 days post-discharge, mortality rate for VHFU was 0.1% (vs 4%) and at 360 days mortality rate for VHFU was 8% (vs 14%). A Cox-Proportional Hazard model showed VHFU adjusting for age, gender, and time period, was associated with a 60% lower mortality rate (Figure 1, Table 1). Conclusion(s): Patients admitted to VHFU had a 60% lower mortality rate compared to those not admitted to the VHFU. Accounting for age, gender and VHFU admission, mortality remained stable from TP2 vs TP1. [Formula presented] [Formula presented]Copyright � 2024 |
URI: | https://hdl.handle.net/20.500.12439/2823 |
DOI: | https://dx.doi.org/10.1016/j.hlc.2024.06.306 |
Type: | Conference abstract |
Keywords: | Australia coronavirus disease 2019 thymostimulin |
Study/Trial: | Observational study (cohort, case-control, cross sectional, or survey) |
Access Rights: | Free article |
Place of publication: | Netherlands |
Conference Name: | 72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand |
Conference Location: | Perth Convention and Exhibition Centre, Perth, Australia |
Appears in Collections: | Conference papers, presentations, and posters |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.